Literature DB >> 20888248

Carcinoid lung tumors--incidence, treatment and outcomes: a population-based study.

Anne Naalsund1, Hans Rostad, Erik Heyerdahl Strøm, May Brit Lund, Trond-Eirik Strand.   

Abstract

OBJECTIVE: Few published reports have examined the incidence and outcomes for patients with carcinoid lung tumors. The aim of the current study was to explore incidence, type of surgical treatment given, and outcome for patients with typical (TC) and atypical (AC) lung carcinoids in a national cohort (Norway).
METHODS: All lung-cancer patients diagnosed in the period 1993-2005 and who were reported to the Cancer Registry of Norway were identified. Biopsies or resection specimens were reviewed and reclassified according to the World Health Organization (WHO) 2004 classification. Surgically treated patients were staged according to the seventh edition of the pathological tumor-node-metastasis (pTNM) staging system.
RESULTS: Of 26665 lung cancers registered during the period, 265 (1%) had carcinoid tumors, of which 11 were diagnosed coincidentally at autopsy. In the remaining 254 patients, TCs were found in 188 cases, and ACs were found in 59 cases; seven cases had unclassifiable carcinoids. Of the 217 resected tumors, 173 (80%) were TCs. General surgeons performed 94 resections, including 11 of 17 pneumonectomies. All six bronchial resections were performed by thoracic surgeons. Of the 33 operated patients who died during follow-up, 18 had metastatic carcinoid tumors, of which 10 (56%) were ACs. In 37 non-resected patients (15 with AC and seven with unclassifiable histology), metastatic or locally advanced disease (N=21, 12 of which were ACs) was the main cause of inoperability and death. Five-year survival for all patients was 92% for TC and 66% for AC; for resected patients, the survival rates were 96% and 79%, respectively.
CONCLUSIONS: Carcinoids are rare malignant tumors and are, in most cases, resectable; the TC subgroup had better prognosis than the AC in univariate analyses. The main cause of death was metastasis/locally advanced tumor at presentation or recurrent disease following resection; both situations were three times more common in patients with AC.
Copyright © 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 20888248     DOI: 10.1016/j.ejcts.2010.08.036

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  31 in total

1.  Do we really care about incidental lung nodules?-Review of atypical lung carcinoid and a proposal for systematic patient follow up.

Authors:  Henal Motiwala; Itisha Bansal; Pradeep Goyal; Olena Dorokhova; Yogesh Kumar; Thomas D Olsavsky; Albert DiMeo; Nishant Gupta
Journal:  Transl Lung Cancer Res       Date:  2017-06

2.  Sustained response to FOLFOX and Bevacizumab in metastatic bronchial carcinoid - A case report and review of the literature.

Authors:  Ikechukwu Akunyili; Monica T Garcia-Buitrago; Jessica Macintyre; Joe Levi; Caio M Rocha Lima
Journal:  J Gastrointest Oncol       Date:  2011-06

3.  Surgical treatment of synchronous multiple neuroendocrine lung tumours (case series): is more always better?

Authors:  Jury Brandolini; Luca Bertolaccini; Alessandro Pardolesi; Piergiorgio Solli
Journal:  Ann Transl Med       Date:  2017-11

4.  Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis.

Authors:  Amir Sabet; Alexander R Haug; Collin Eiden; Christoph J Auernhammer; Birgit Simon; Peter Bartenstein; Hans J Biersack; Samer Ezziddin
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-04-15

Review 5.  Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.

Authors:  Giuseppe Lo Russo; Sara Pusceddu; Natalie Prinzi; Martina Imbimbo; Claudia Proto; Diego Signorelli; Milena Vitali; Monica Ganzinelli; Marco Maccauro; Roberto Buzzoni; Ettore Seregni; Filippo de Braud; Marina Chiara Garassino
Journal:  Tumour Biol       Date:  2016-07-27

Review 6.  Challenges in the Diagnosis and Management of Well-Differentiated Neuroendocrine Tumors of the Lung (Typical and Atypical Carcinoid): Current Status and Future Considerations.

Authors:  Edward M Wolin
Journal:  Oncologist       Date:  2015-08-25

7.  Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study.

Authors:  Claudia Pivonello; Panagoula Rousaki; Mariarosaria Negri; Maddalena Sarnataro; Maria Napolitano; Federica Zito Marino; Roberta Patalano; Maria Cristina De Martino; Concetta Sciammarella; Antongiulio Faggiano; Gaetano Rocco; Renato Franco; Gregory A Kaltsas; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2016-09-29       Impact factor: 3.633

8.  Pulmonary carcinoid tumours: incidence, histology, and surgical outcome. A population-based study.

Authors:  Astridur Petursdottir; Johanna Sigurdardottir; Bjorn M Fridriksson; Arni Johnsen; Helgi J Isaksson; Hronn Hardardottir; Steinn Jonsson; Tomas Gudbjartsson
Journal:  Gen Thorac Cardiovasc Surg       Date:  2019-11-28

9.  Incidental detection of bronchial carcinoid on Tc-99m sestamibi SPECT/CT myocardial perfusion scintigraphy.

Authors:  Dharmender Malik; Apurva Sood; Madan Parmar; Ashwani Sood; Bishan Radotra; Bhagwant Mittal
Journal:  J Nucl Cardiol       Date:  2016-02-17       Impact factor: 5.952

10.  Association of carcinoid tumor and low grade glioma.

Authors:  Emeline Tabouret; Maryline Barrié; Cecile Vicier; Anthony Gonçalves; Olivier Chinot; Patrice Viens; Anne Madroszyk
Journal:  World J Surg Oncol       Date:  2012-11-08       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.